Clinical Trial Update: Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary [Phase 2]

View source ↗

Summary

Phase II clinical trial evaluating Lu-177 FAP-2286 for carcinoma of unknown primary; the study status is NOT_YET_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer of Unknown Primary

Drugs mentioned

• Lu-177 FAP-2286 (Lutetium-177 FAP-2286)

Snippet

Sponsor: Peter MacCallum Cancer Centre, Australia | Conditions: Cancer of Unknown Primary | Phase 2 | Status: NOT_YET_RECRUITING